NEW YORK (GenomeWeb News) – Researchers from the National Cancer Institute have sequenced the protein-coding portions of the NCI-60 human cancer cell line genomes, using the data to look for genetic contributors to drug response in the well-characterized cell line panel.

As they reported online today in Cancer Research, the researchers initially used whole-exome sequence data for the 60 cancer cell lines to put together a list of mutations suspected of being cancer-specific.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.